IH
Ivan Hyep
Chief Financial Officer

Ivan Hyep insider trades: Bicara Therapeutics (BCAX) stock sales

Chief Financial Officer, Bicara Therapeutics Last trade Aug 10, 2026 11 Form 4 filings
$2.5M
Sold, last 12 months
8 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2025
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Ivan reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 10, 2026BCAX↓ Sell$350K
Jul 8, 2026BCAX↓ Sell$808K
May 21, 2026BCAX↓ Sell$188K
Apr 21, 2026BCAX↓ Sell$212K
Mar 23, 2026BCAX↓ Sell$170K
Mar 4, 2026BCAX↓ Sell$301K
Dec 22, 2025BCAX↓ Sell$168K
Nov 24, 2025BCAX↓ Sell$341K
Oct 9, 2025BCAX↓ Sell$117K
Oct 8, 2025BCAX↓ Sell$553K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other BCAX insiders

Open-market trades in the last 12 months

About Ivan Hyep's insider trades

Ivan Hyep is Chief Financial Officer at Bicara Therapeutics (BCAX). Since Oct 8, 2025, Ivan has reported no open-market purchases and 10 sales worth $3.2M on SEC Form 4. In the last 12 months: 8 sales ($2.5M).

Their filings also include option exercises (10 filings), grants and awards (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCAX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.